How much revenue does Beijing Foyou Pharma make?

Beijing Foyou Pharma reported 3.45 billion CNY in revenue for fiscal year 2024, up 3.2% from 3.34 billion CNY in fiscal year 2023. In Q2 2025 revenue was 803.50 million CNY.

What is Beijing Foyou Pharma's largest business segment?

Medicine, with 3.31 billion CNY or 94% of segment revenue in fiscal year 2025. Next: Medical Instruments (6%).

Where does Beijing Foyou Pharma make most of its revenue?

East China: 40% of revenue by region in fiscal year 2025, followed by North China (15%).

What companies are similar to Beijing Foyou Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Wanbangde Pharmaceutical Holding Group Co., Ltd. (002082.SZ), Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS), Changzhou Qianhong Biopharma Co.,ltd (002550.SZ), Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ).

Beijing Foyou Pharma Co.,ltd (601089.SS) Stock

About Beijing Foyou Pharma Co.,ltd

Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical formulation and medical devices China. The company offers chemical drugs; traditional Chinese medicine; raw materials; and medical devices, such as negative pressure drainage device, digital urine collection bags, dynamic urine output monitor, disposable pressure sensor, urodynamic monitori...

At a glance

Beijing Foyou Pharma reported revenue of 3.45 billion CNY for fiscal year 2024, up 3.2% from fiscal year 2023, and net income of 488.67 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 803.50 million CNY, down 5.8% from a year before. Its largest business segment, Medicine, brought in 94% of segment revenue in fiscal year 2025; East China was the largest region with 40%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.